Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results
- PMID: 23943669
- PMCID: PMC3740810
Item in Clipboard
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results
Gastroenterol Hepatol (N Y).
2013 May.
No abstract available
Similar articles
-
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.Lancet Gastroenterol Hepatol. 2021 Aug;6(8):616-627. doi: 10.1016/S2468-1253(21)00142-4. Epub 2021 Jun 19. Lancet Gastroenterol Hepatol. 2021. PMID: 34153231 Clinical Trial.
-
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4. Gastroenterology. 2012. PMID: 22062358 Clinical Trial.
-
Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.Int J Clin Exp Med. 2015 Jan 15;8(1):86-93. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25784977 Free PMC article.
-
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.Scand J Gastroenterol. 2019 Feb;54(2):178-187. doi: 10.1080/00365521.2019.1569124. Epub 2019 Feb 8. Scand J Gastroenterol. 2019. PMID: 30735443
-
Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Expert Opin Biol Ther. 2017 May;17(5):613-621. doi: 10.1080/14712598.2017.1309390. Epub 2017 Mar 28. Expert Opin Biol Ther. 2017. PMID: 28316250 Review.
Cited by
-
Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.Dig Dis Sci. 2018 Oct;63(10):2740-2746. doi: 10.1007/s10620-018-5176-3. Epub 2018 Jun 27. Dig Dis Sci. 2018. PMID: 29951797 Free PMC article.
-
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.Inflamm Bowel Dis. 2018 Nov 29;24(12):2527-2542. doi: 10.1093/ibd/izy189. Inflamm Bowel Dis. 2018. PMID: 29788338 Free PMC article. Review.
-
Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial.J Gastroenterol. 2020 Apr;55(4):390-400. doi: 10.1007/s00535-019-01651-0. Epub 2019 Dec 6. J Gastroenterol. 2020. PMID: 31811562 Clinical Trial.
-
Current new challenges in the management of ulcerative colitis.Intest Res. 2019 Jan;17(1):36-44. doi: 10.5217/ir.2018.00126. Epub 2019 Jan 25. Intest Res. 2019. PMID: 30678445 Free PMC article.
-
Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis.J Can Assoc Gastroenterol. 2024 Oct 29;8(1):21-30. doi: 10.1093/jcag/gwae040. eCollection 2025 Feb. J Can Assoc Gastroenterol. 2024. PMID: 39906279 Free PMC article.
References
-
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476. - PubMed
-
- Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787. - PubMed
-
- Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265-e13. - PubMed
LinkOut - more resources
Full Text Sources